While markets focus on the science, we focus on the stewardship of that science. Our approach evaluates trial design and execution quality through the lens of deep-domain operational experience - uncovering opportunities markets systematically overlook.

We invest selectively in small- to mid-cap biopharma where pivotal trials decide outcomes. Our high-conviction, long-only strategy is designed to identify the programs most likely to reach the finish line through rigorous execution.